NVX-CoV2373 + Matrix-M

NVX-CoV2373 + Matrix-M is a **combination COVID-19 vaccine** composed of a recombinant, prefusion-stabilized, full-length SARS-CoV-2 spike protein nanoparticle (NVX-CoV2373) formulated with the Matrix-M adjuvant. The vaccine leverages a **baculovirus/Sf9 insect cell expression system** to produce spike protein nanoparticles that closely mimic the native viral antigenic structure. Matrix-M is a saponin-based adjuvant made from *Quillaja saponaria* fractions (Matrix-A and Matrix-C nanoparticles), engineered to stimulate robust Th1-skewed cell-mediated and humoral immune responses by enhancing antigen presentation and immune cell activation at the injection site and draining lymph nodes. NVX-CoV2373 + Matrix-M induces high titers of neutralizing antibodies, CD4+ and CD8+ T cells, and memory B cells, providing protection against SARS-CoV-2 infection. It is approved or authorized in multiple countries for the prevention of COVID-19 in adults and has demonstrated efficacy and safety in phase III clinical trials[1][2][3][4][5][6].

Brand names

NuvaxovidNovavax COVID-19 Vaccine, Adjuvanted

Other names

Novavax COVID-19 vaccinerecombinant spike protein + Matrix-M adjuvant